SCHEMBL810583

SCHEMBL810583

COc1ccccc1COc1ccc(Sc2ccc(O)cc2)c(Nc2ncnc3ncccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.64
AKT2 P31751 1/20 0.64
MAPK1 P28482 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RET P07949 5/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EGFR P00533 4/20 0.36
ERBB2 P04626 1/20 0.36
ERBB4 Q15303 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
TNNI3K Q59H18 1/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDR P35968 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810438 0.90 PIM1 (0.68) PIM1AKT2RETMAPTEGFR
SCHEMBL811074 0.88 PIM1 (0.78) PIM1AKT2MAPTEGFRERBB2
SCHEMBL810323 0.87 PIM1 (0.57) PIM1AKT2MAPK1ALDH1A1HPGD
SCHEMBL810618 0.87 PIM1 (0.57) PIM1AKT2RETMAPTEGFR
SCHEMBL810736 0.86 PIM1 (0.66) PIM1AKT2MAPK1ALDH1A1HPGD
SCHEMBL810273 0.86 PIM1 (0.60) PIM1AKT2HPGDSMN1; SMN2MAPT
SCHEMBL810758 0.86 PIM1 (0.65) PIM1AKT2MAPK1ALDH1A1HPGD
SCHEMBL810397 0.85 PIM1 (0.55) PIM1AKT2MAPK1ALDH1A1HPGD
SCHEMBL810344 0.84 PIM1 (0.59) PIM1AKT2SMN1; SMN2MAPTEGFR
SCHEMBL810060 0.82 PIM1 (0.58) PIM1AKT2MAPTEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAPK1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.